SCHEMBL5433646

SCHEMBL5433646

C=C1CC[C@H](O[Si](C)(C)C(C)(C)C)C/C1=C\C=C1/CCC[C@]2(C)[C@@H]([C@H](C)CC[C@H](O)C(C)C)CC[C@@H]12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VDR P11473 7/20 0.60
MAPT P10636 5/20 0.59
SMN1; SMN2 Q16637 3/20 0.59
SREBF1 P36956 1/20 0.59
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
ALDH1A1 P00352 3/20 0.57
ALOX15 P16050 3/20 0.57
CYP3A4 P08684 2/20 0.57
PGR P06401 2/20 0.57
ADORA3 P0DMS8 2/20 0.57
TDP1 Q9NUW8 1/20 0.57
CDC25A P30304 1/20 0.57
HSPD1 P10809 1/20 0.57
HPGD P15428 1/20 0.57
TBXA2R P21731 1/20 0.57
PTGS1 P23219 1/20 0.57
GLRA1 P23415 1/20 0.57
DRD3 P35462 1/20 0.57
HSPE1 P61604 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5437551 1.00 VDR (0.60) VDRMAPTSMN1; SMN2SREBF1MEN1
SCHEMBL8769851 0.91 MAPT (0.60) VDRMAPTSMN1; SMN2SREBF1MEN1
SCHEMBL8090430 0.90 MAPT (0.57) VDRMAPTSMN1; SMN2SREBF1MEN1
SCHEMBL7264390 0.90 VDR (0.69) VDRMAPTSMN1; SMN2SREBF1MEN1
SCHEMBL14112585 0.89 MAPT (0.56) VDRMAPTSMN1; SMN2SREBF1MEN1
SCHEMBL20461021 0.89 ALDH1A1 (0.54) VDRMAPTSMN1; SMN2SREBF1MEN1
SCHEMBL18021750 0.89 ALDH1A1 (0.54) VDRMAPTSMN1; SMN2SREBF1MEN1
SCHEMBL20461000 0.89 ALDH1A1 (0.54) VDRMAPTSMN1; SMN2SREBF1MEN1
SCHEMBL18023732 0.89 ALDH1A1 (0.54) VDRMAPTSMN1; SMN2SREBF1MEN1
SCHEMBL8770493 0.88 MAPT (0.56) VDRMAPTSMN1; SMN2SREBF1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070088007-A1 Method for preparing analogue of vitamin D FORMOSA LABORATORIES, INC. (TW) 2007-04-19 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070088007-A1 Method for preparing analogue of vitamin D CYP24A1, CYP2R1, VDR VDR 3/4885MAPT 4595/4885SMN1; SMN2 4801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.